Adc Therapeutics Sa Stock Price, News & Analysis

ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-month progression-free survival of 94.6%. The study enrolled 39 patients with a median age of 68 years.

In the second trial, ZYNLONTA as monotherapy for relapsed/refractory marginal zone lymphoma demonstrated a 91% overall response rate and 70% complete response rate in 23 patients. The median duration of complete response was 11.5 months, with the longest follow-up at 27 months.

ADC Therapeutics (NYSE: ADCT) has announced a conference call and webcast scheduled for December 11, 2024, at 8:30 a.m. EST. The company will present preliminary data from the LOTIS-7 Phase 1b clinical trial, which evaluates ZYNLONTA® in combination with bispecific antibody glofitamab (COLUMVI™) for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

The conference call will be accessible via toll-free dial-in for North America and Canada participants, and a webcast will be available on the company's investor relations website for 30 days following the presentation.

ADC Therapeutics announced the granting of options to purchase 34,900 common shares to three new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.

ADC Therapeutics reported Q3 2024 financial results with ZYNLONTA® net product revenues of $18.0 million, up from $14.3 million in Q3 2023. The company reported a net loss of $44.0 million ($0.42 per share) compared to $46.7 million in Q3 2023. Key operational updates include expected full enrollment in LOTIS-5 trial by year-end 2024, continued LOTIS-7 enrollment with interim data expected in December, and discontinuation of the ADCT-601 program. Cash position stands at $274.3 million, with runway extended into mid-2026 following a $97.4 million offering in May 2024.

ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphoma showed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic response rate. In a separate study for relapsed/refractory marginal zone lymphoma, ZYNLONTA as a single agent achieved an 85% overall response rate with 75% complete response rate in 20 evaluable patients. Both studies demonstrated safety profiles consistent with known ZYNLONTA data.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has announced its participation in two major investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 11:00 a.m. ET, and the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. GMT. Both presentations will feature CEO Ameet Mallik in fireside chat formats. Live webcasts will be available on the company's investor relations website, with replays accessible for approximately 30 days after each event.

ADC Therapeutics announced the grant of options to purchase 42,000 common shares to two new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, subject to continued employment.

ADC Therapeutics (NYSE: ADCT) announced it will host a conference call and live webcast on November 7, 2024, at 8:30 a.m. EST to discuss third quarter 2024 financial results and provide business updates. North American and Canadian participants can join via toll-free number 1-800-836-8184. The webcast will be available under 'Events and Presentations' on the company's investor relations website and archived for 30 days after the call.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody drug conjugates (ADCs), has announced the granting of options to purchase 113,700 common shares to six new employees on October 1, 2024. These grants were approved by the Compensation Committee of the Company's Board of Directors under the Company's Inducement Plan as a material inducement to employment.

The options will vest and become exercisable in stages: 25% on the first anniversary of the grant date, and 1/48th monthly thereafter, becoming fully vested after four years, subject to continued employment. This action aligns with NYSE's Listed Company Manual Rule 303A.08, emphasizing ADC Therapeutics' commitment to attracting and retaining top talent in the competitive field of ADCs.